S55. THERAPEUTIC MANAGEMENT OF PATIENTS DIAGNOSED WITH SCHIZOPHRENIA AND MAJOR NEUROCOGNITIVE DISORDER DUE TO ALZHEIMER’S DISEASE - A CASE SERIES

Abstract. Two clients seeking neuropsychological assessment reported anxiety about their cognitive status. We review the cases to increase our understanding of factors contributing to dementia-related anxiety. Case 1 met the criteria for mild neurocognitive disorder; the client’s memory was impaired, and she had a high genetic risk for Alzheimer’s disease. The client reported anxiety about negative perceptions of quality of life among individuals diagnosed with Alzheimer’s disease. Case 2 did not meet the criteria for a neurocognitive disorder. Anxiety about this client’s cognitive status appeared attributable to generalized anxiety disorder, given his anxiety about diverse topics. Both clients reported embarrassment about forgetfulness and social withdrawal. Dementia-related anxiety is believed to be relatively common, to exist on a continuum, to have unique social implications, and to stem from various sources, necessitating differing interventions.

Download Full-text

Death Rate Due to COVID-19 in Alzheimer’s Disease and Frontotemporal Dementia

Journal of Alzheimer s Disease ◽

10.3233/jad-200940 ◽

2020 ◽

Vol 78 (2) ◽

pp. 537-541

Author(s):

Jordi A. Matias-Guiu ◽

Vanesa Pytel ◽

Jorge Matías-Guiu

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Frontotemporal Dementia ◽

Death Rate ◽

Case Series ◽

Care Homes ◽

Relevant Factor ◽

Increased Risk ◽

Care Facilities ◽

Probability Of Death

We aimed to evaluate the frequency and mortality of COVID-19 in patients with Alzheimer’s disease (AD) and frontotemporal dementia (FTD). We conducted an observational case series. We enrolled 204 patients, 15.2% of whom were diagnosed with COVID-19, and 41.9% of patients with the infection died. Patients with AD were older than patients with FTD (80.36±8.77 versus 72.00±8.35 years old) and had a higher prevalence of arterial hypertension (55.8% versus 26.3%). COVID-19 occurred in 7.3% of patients living at home, but 72.0% of those living at care homes. Living in care facilities and diagnosis of AD were independently associated with a higher probability of death. We found that living in care homes is the most relevant factor for an increased risk of COVID-19 infection and death, with AD patients exhibiting a higher risk than those with FTD.

Download Full-text

Effects of depression on cognition of patients with mild neurocognitive disorder due to possible Alzheimer’s disease

Ciencias Psicológicas ◽

10.22235/cp.v11i2.1486 ◽

2017 ◽

pp. 149

Author(s):

Charles Ysaacc Da Silva Rodrigues ◽

Paula Carvalho Figueiredo ◽

Hidekel Quino Montes ◽

Marta Gruart Vila

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Neurocognitive Disorder ◽

Mild Neurocognitive Disorder

Objetivo: Identificar el nivel de relación entre la depresión y las funciones cognitivas del enfermo de Alzheimer en fase inicial. Cuadro teórico: La depresión es factor de riesgo para las demencias y consecuentemente para la enfermedad de Alzheimer (EA), debido a la pérdida de memoria, que tiende a asociarse con dificultades de orientación, de aprendizaje y reconocimiento. Metodología: Participaron en esta investigación un total de 142 adultos mayores divididos en dos grupos, con y sin diagnóstico clínico de Alzheimer y depresión. Los participantes fueron evaluados a través de la aplicación del Inventario de Depresión de Beck II (BDI-II), y el Mini Mental (MME) de Folstein. Resultados: Se encontraron efectos estadísticamente significativos entre cognición y depresión en adultos mayores con EA, en fase inicial. Conclusiones: Se concluye que existe una alta posibilidad de cambios cognoscitivos del enfermo con Alzheimer, cuando su enfermedad se encuentra asociada a la depresión. Además, los resultados apuntan a la cognición como factor responsable de las alteraciones conductuales del enfermo, como consecuencia del empeoramiento de la depresión.

Download Full-text

Major or Mild Neurocognitive Disorder due to Alzheimer’s Disease

The SAGE Encyclopedia of Abnormal and Clinical Psychology ◽

10.4135/9781483365817.n808 ◽

2017 ◽

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Neurocognitive Disorder ◽

Mild Neurocognitive Disorder

Download Full-text

Involvement of organelles and inter-organellar signaling in the pathogenesis of HIV-1 associated neurocognitive disorder and Alzheimer’s disease

Brain Research ◽

10.1016/j.brainres.2019.146389 ◽

2019 ◽

Vol 1722 ◽

pp. 146389 ◽

Cited By ~ 2

Author(s):

Nabab Khan ◽

Norman J. Haughey ◽

Avindra Nath ◽

Jonathan D. Geiger

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Neurocognitive Disorder ◽

Hiv 1

Download Full-text

Phonological and Articulatory Impairment in Alzheimer's Disease: A Case Series

Brain and Language ◽

10.1006/brln.2000.2357 ◽

2000 ◽

Vol 75 (2) ◽

pp. 277-309 ◽

Cited By ~ 53

Author(s):

Karen Croot ◽

John R. Hodges ◽

John Xuereb ◽

Karalyn Patterson

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Case Series

Download Full-text

Cholinesterase Inhibitors and Memantine: Best Practices

CNS Spectrums ◽

10.1017/s1092852900027048 ◽

2008 ◽

Vol 13 (S16) ◽

pp. 34-35 ◽

Cited By ~ 6

Author(s):

Rachelle S. Doody

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Best Practices ◽

Cholinesterase Inhibitors ◽

Treatment Guidelines ◽

Case Reports ◽

Case Series ◽

Added Value ◽

Case Control Studies ◽

Number Of Patients

Today’s therapies must be put in the context of both currently available treatments as well as treatment trials with exciting potential for use in the near future. Current clinical trial methodologies do not allow for clear separation of symptomatic treatments from disease-modifying therapies; it may be unproductive to maintain this distinction given the current range of treatments available. A more currently relevant focus is added value. Therapies should aim to provide added value through incremental benefits above and beyond existing treatments, as well as enduring benefits.Alzheimer’s disease (AD) treatment guidelines are not used by physicians only. Healthcare payers often make use of these guidelines to delimit coverage. Cost concerns will also impact AD treatments after generic cholinesterase inhibitors are made available; it is widely believed that a great number of patients will switch to generics. Therefore, treatment guidelines must account for the possible adverse effects of switching therapies as well as the desirability of persistent treatment. There are many AD treatment guidelines, among them the American Academy of Neurology (AAN) Management of Dementia Guidelines, which are currently being revised. The Institute for the Study on Aging (ISOA) Management of Alzheimer’s Disease in Managed Care Guideline also presents a different approach for a different audience.The first step to creating evidence-based best practices guidelines is to determine what is meant by “evidence.” A system of classification exists for examining forms of evidence: Class I evidence is provided by one or more well-designed, randomized, controlled clinical trials, including overviews or meta-analyses of such trials. Class II evidence is provided by well-designed observational studies with concurrent controls; for example, case-control studies that generate hypotheses about epidemiologic associations. Class III evidence is provided by expert opinion, case series, case reports, and studies with historical controls.

Download Full-text